Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marcelo de Souza R. de Oliveira"'
Publikováno v:
Arquivos de Neuro-Psiquiatria, Vol 63, Iss 2a, Pp 225-227 (2005)
Mitoxantrone hydrochloride (Novantrone®) is an anthracenedione that has been used as one of the latest in a long line of general immunosuppresive agents studied in multiple sclerosis (MS). We reviewed the clinical, laboratory, neuroimaging and echoc
Externí odkaz:
https://doaj.org/article/23e9eaa34bf84793913c14b672618515
Publikováno v:
Arquivos de Neuro-Psiquiatria, Vol 63, Iss 2a, Pp 327-329 (2005)
Mitoxantrone (MX) is an immunosupressant drug used in secondarily progressive multiple sclerosis (SPMS) and in relapsing-remitting multiple sclerosis (RRMS). It has a leukemogenesis potential induced by cytogenetic abnormalities, though with a low in
Externí odkaz:
https://doaj.org/article/ed156a80a383481381b09406dd3bf6f5
Autor:
Ricardo Ramina, Mônica Lima, Luis Fernando Moura da Silva, Maurício Coelho Neto, Marcelo de Souza R. de Oliveira
Publikováno v:
JBNC - JORNAL BRASILEIRO DE NEUROCIRURGIA. 24:107-112
The temozolomide protocol established in 2005 increased overall survival rates in patients with glioblastoma. It defined a treatment period of 6 months, but most neuro-oncological centers prescribe more than this, reaching up to 3 years of continuous
Publikováno v:
Arquivos de Neuro-Psiquiatria, Volume: 63, Issue: 2a, Pages: 327-329, Published: JUN 2005
Arquivos de Neuro-Psiquiatria v.63 n.2a 2005
Arquivos de neuro-psiquiatria
Academia Brasileira de Neurologia
instacron:ABNEURO
Arquivos de Neuro-Psiquiatria v.63 n.2a 2005
Arquivos de neuro-psiquiatria
Academia Brasileira de Neurologia
instacron:ABNEURO
Mitoxantrone (MX) is an immunosupressant drug used in secondarily progressive multiple sclerosis (SPMS) and in relapsing-remitting multiple sclerosis (RRMS). It has a leukemogenesis potential induced by cytogenetic abnormalities, though with a low in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec14a9075d170c7cb023fa780ce6b6d8
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000200024&lng=en&tlng=en
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000200024&lng=en&tlng=en
Autor:
Carlos Henrique Ferreira Camargo, Ivar V. Brandi, Rosana Herminia Scola, Marcelo de Souza R. de Oliveira, Lineu Cesar Werneck, Nilson Becker, Gilmar C. Silva, Maurício M. Roriz, Hélio A.G. Teive, Marise Bueno Zonta
Publikováno v:
ResearcherID
Arquivos de Neuro-Psiquiatria, Volume: 67, Issue: 1, Pages: 62-68, Published: MAR 2009
Arquivos de Neuro-Psiquiatria v.67 n.1 2009
Arquivos de neuro-psiquiatria
Academia Brasileira de Neurologia
instacron:ABNEURO
Arquivos de Neuro-Psiquiatria, Volume: 67, Issue: 1, Pages: 62-68, Published: MAR 2009
Arquivos de Neuro-Psiquiatria v.67 n.1 2009
Arquivos de neuro-psiquiatria
Academia Brasileira de Neurologia
instacron:ABNEURO
We evaluated the safety and effectiveness of botulinum toxin A (BoNT/A) in the treatment of spasticity in 20 children with spastic diplegic cerebral palsy (CP). All the patients received injections in the gastrocnemius and soleus, and 15 received inj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fd6c9b843421be4e62e296194dd9d67
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000264693900016&KeyUID=WOS:000264693900016
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000264693900016&KeyUID=WOS:000264693900016